Cigarette Smoking-Related CarcinomaNCT07604246
Evaluating the Effect of Nicotine on Eye Movements and Related Behaviors in Electronic Cigarette Users, NICS-EYES Trial
A study testing Avoidance, Biospecimen Collection and Cigarette Smoking in people with Cigarette Smoking-Related Carcinoma, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
Trial summary
This clinical trial evaluates the effect of nicotine on eye movements and related behaviors in people who use electronic (e)-cigarettes. Nicotine is an addictive, poisonous chemical found in tobacco. It can also be made in the laboratory. Read more about this study
- Who is it for?
- Ages 21 to 50 years
- Conditions the study is for
- Cigarette Smoking-Related Carcinoma
- What is being tested?
- Avoidance, Biospecimen Collection and Cigarette Smoking
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Aug 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age 21-50 years
- Daily use of nicotine-containing electronic cigarettes for ≥ 6 months
- Ability to abstain from nicotine for at least 12 hours prior to study visits
- Fluent in English
- Willingness to complete two in-person laboratory visits and all study procedures
- Ability to provide informed consent
Who cannot join
- Use of combustible cigarettes or other tobacco/nicotine products on more than 5 of the past 30 days
- Current enrollment in a nicotine cessation program or intent to quit in the next 30 days
- Neurological conditions affecting eye movements (seizure disorder, movement disorders, head injury with loss of consciousness)
- Normal or corrected-to-normal vision required; significant uncorrected visual impairment or ocular conditions affecting eye tracking
- Cardiovascular conditions for which nicotine use is contraindicated, substance use disorder (other than nicotine), or current nicotine cessation treatment
- Pregnancy or breastfeeding
Show all 9Show fewer
- Current medications affecting pupil size or eye movements (anticholinergics, stimulants, antipsychotics)
- Any condition that, in the investigator's judgment, would interfere with safe participation
- Age younger than 21 years or older than 50 years
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
The Ohio State University Comprehensive Cancer Center contact
United States1 site, 1 recruiting
- Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Patrick Tomko, PhD, CSCS, 614-293-8152, patrick.tomko@osumc.edu
Patrick Tomko, PhD, CSCS
About this study
Official title: Nicotine Effects on Eye Movements and Self-Report Measures (NICS-EYES)
This clinical trial evaluates the effect of nicotine on eye movements and related behaviors in people who use electronic (e)-cigarettes. Nicotine is an addictive, poisonous chemical found in tobacco. It can also be made in the laboratory. When it enters the body, nicotine causes an increased heart rate and the use of oxygen by the heart and a sense of well-being and relaxation. E-cigarettes are the most commonly used tobacco products in young adults in the United States. E-cigarettes deliver nicotine rapidly and the potential for addiction (abuse liability) is comparable to combustible cigarettes. The Food and Drug Administration uses a combination of testing including self-reported scales, withdrawal assessments and behavioral tasks to evaluate the abuse liability of a nicotine product. Research has shown that nicotine alters movement of the eye (oculomotor) and the amount of nicotine in the blood impacts the extent of oculomotor function impairment. Despite this evidence linking nicotine to oculomotor changes, it has not been studied as a reliable marker for abuse in e-cigarette users. Studying eye movements can provide information about how the brain responds to nicotine and may help researchers develop better, more objective ways to measure how addictive nicotine products in e-cigarette users.
Read the detailed description
PRIMARY OBJECTIVE:
- To determine the between-session reliability of oculomotor biomarkers during standardized nicotine administration in daily e-cigarette users.
SECONDARY OBJECTIVES:
- To evaluate the association between oculomotor (OM) responses to nicotine and behavioral economic indices of reinforcing value.
II. To assess the relationship between oculomotor changes and nicotine withdrawal relief.
OUTLINE:
Participants abstain from nicotine for at least 12 hours and caffeine products for at least 2 hours, as well as obtain sleep for at least 5-6 hours before each study visit. Participants self-administer 5% nicotine non-mint menthol pods via an e-cigarette device using a guided standardized puffing routine over 5 minutes on visit one. At least 48 hours later, participants complete the same 5-minute guided puffing routine as in visit one and then use an e-cigarette as they normally would over 30 minutes at visit two. Participants also complete eye movement testing and undergo blood sample collection during each visit.
- Conditions
- Cigarette Smoking-Related Carcinoma
- Being tested
- Avoidance, Biospecimen Collection, Cigarette Smoking, Eye Movement Measurement, Healthcare Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AvoidanceBehavioural
Also called Avoided
Abstain from caffeine products
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo blood sample collection
Cigarette SmokingBehavioural
Complete self-administer 5% nicotine non-mint menthol pods via an e-cigarette device
Eye Movement MeasurementProcedure or surgery
Complete eye movement testing
Healthcare ActivityBehavioural
Also called Health Care, Health Care Activity, Healthcare
Obtain sleep
Questionnaire AdministrationOther
Ancillary studies
Refrain from SmokingBehavioural
Also called Abstain from Smoking, Abstinence from Cigarette Smoking, Abstinence from Cigarettes, Smoking Abstinence
Abstain from nicotine
VapingOther
Also called Vape
Complete ad-libitum e-cigarette vaping
Standardized E-Cigarette Nicotine AdministrationDrug
Participants use a e-cigarette 5.0% nicotine mint menthol pods. Visit 1: 5-minute guided puffing session (standardized protocol). Visit 2: 5-minute guided session followed by 30-minute ad-libitum vaping phase. Puffing topography monitored via SPA-Neo device.
| Study group | Role | What they receive |
|---|---|---|
| Basic science (e-cigarette smoking, eye movement testing) | Experimental | Participants abstain from nicotine for at least 12 hours and caffeine products for at least 2 hours, as well as obtain sleep for at least 5-6 hours before each study visit. Participants self-administer 5% nicotine mint menthol via an e-cigarette device using a guided standardized puffing routine over 5 minutes on visit one. At least 48 hours later, participants complete the same 5-minute guided puffing routine as in visit one and then use an e-cigarette as they normally would over 30 minutes at visit two. Participants also complete eye movement testing and undergo blood sample collection during each visit. Receives: Behavioral: Avoidance; Procedure: Biospecimen Collection; Behavioral: Cigarette Smoking; Procedure: Eye Movement Measurement; Behavioral: Healthcare Activity; Other: Questionnaire Administration; Behavioral: Refrain from Smoking; Other: Vaping; Drug: Standardized E-Cigarette Nicotine Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in prosaccade latency and velocity
Reliability will be assessed using intraclass correlation coefficients (ICCs). Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures analysis of variance (ANOVA), as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.
Measured: At baseline and at 5, 15 and 30 minutes post-nicotine administration, assessed up to completion of visit 2, up to 3 weeks
Change in antisaccade error rate and latency
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.
Measured: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Change in smooth pursuit gain across two laboratory sessions
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.
Measured: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Change in oculomotor performance
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.
Measured: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Plasma nicotine maximum concentration
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
Time to maximum concentration of plasma nicotine
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
Plasma nicotine area under the curve
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
Subjective drug liking ratings
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between subjective ratings and behavioral economic measures will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
Secondary outcomes (4)
Electronic (E)-cigarette intensity demand
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
E-cigarette Omax
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
E-cigarette demand breakpoint
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Measured: Up to completion of visit 2, up to 3 weeks
Change in Minnesota Nicotine Withdrawal Scale scores
The Minnesota Nicotine Withdrawal Scale (MNWS) will asses nicotine withdrawal and craving, anger/irritability, anxiety, depressed mood, restlessness/difficulty concentrating, increased appetite, sleep problems, and somatic symptoms (nausea, constipation, sore throat, dizziness, coughing). Scores range from 0 to 4 with higher scores indicating greater levels of withdrawal. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Measured: From baseline and following nicotine administration, assessed up to completion of visit 2, up to 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start17 Aug 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cigarette Smoking-Related CarcinomaStudies of the same condition, open and under way.
- More trials run by Ohio State University Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Patrick Tomko, Ohio State University Comprehensive Cancer Center
- Investigators
- Patrick Tomko, PhD, CSCS, Principal investigator, Ohio State University Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07604246
- Sponsor's protocol ID
- OSU-26020
- Other IDs
- NCI-2026-03442, STUDY20252989
- Status last verified
- Sep 2026
- First submitted
- 18 May 2026
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nicotine Effects on Eye Movements and Self-Report Measures (NICS-EYES)
- ClinicalTrials.gov ID
- NCT07604246
- Acronym / sponsor ID
- OSU-26020
- Conditions
- Cigarette Smoking-Related Carcinoma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 17 Aug 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial evaluates the effect of nicotine on eye movements and related behaviors in people who use electronic (e)-cigarettes. Nicotine is an addictive, poisonous chemical found in tobacco. It can also be made in the laboratory. When it enters the body, nicotine causes an increased heart rate and the use of oxygen by the heart and a sense of well-being and relaxation. E-cigarettes are the most commonly used tobacco products in young adults in the United States. E-cigarettes deliver nicotine rapidly and the potential for addiction (abuse liability) is comparable to combustible cigarettes. The Food and Drug Administration uses a combination of testing including self-reported scales, withdrawal assessments and behavioral tasks to evaluate the abuse liability of a nicotine product. Research has shown that nicotine alters movement of the eye (oculomotor) and the amount of nicotine in the blood impacts the extent of oculomotor function impairment. Despite this evidence linking nicotine to oculomotor changes, it has not been studied as a reliable marker for abuse in e-cigarette users. Studying eye movements can provide information about how the brain responds to nicotine and may help researchers develop better, more objective ways to measure how addictive nicotine products in e-cigarette users.
Detailed description
PRIMARY OBJECTIVE:
- To determine the between-session reliability of oculomotor biomarkers during standardized nicotine administration in daily e-cigarette users.
SECONDARY OBJECTIVES:
- To evaluate the association between oculomotor (OM) responses to nicotine and behavioral economic indices of reinforcing value.
II. To assess the relationship between oculomotor changes and nicotine withdrawal relief.
OUTLINE:
Participants abstain from nicotine for at least 12 hours and caffeine products for at least 2 hours, as well as obtain sleep for at least 5-6 hours before each study visit. Participants self-administer 5% nicotine non-mint menthol pods via an e-cigarette device using a guided standardized puffing routine over 5 minutes on visit one. At least 48 hours later, participants complete the same 5-minute guided puffing routine as in visit one and then use an e-cigarette as they normally would over 30 minutes at visit two. Participants also complete eye movement testing and undergo blood sample collection during each visit.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Basic science (e-cigarette smoking, eye movement testing) | Experimental | Behavioral: Avoidance, Procedure: Biospecimen Collection, Behavioral: Cigarette Smoking, Procedure: Eye Movement Measurement, Behavioral: Healthcare Activity, Other: Questionnaire Administration, Behavioral: Refrain from Smoking, Other: Vaping, Drug: Standardized E-Cigarette Nicotine AdministrationParticipants abstain from nicotine for at least 12 hours and caffeine products for at least 2 hours, as well as obtain sleep for at least 5-6 hours before each study visit. Participants self-administer 5% nicotine mint menthol via an e-cigarette device using a guided standardized puffing routine over 5 minutes on visit one. At least 48 hours later, participants complete the same 5-minute guided puffing routine as in visit one and then use an e-cigarette as they normally would over 30 minutes at visit two. Participants also complete eye movement testing and undergo blood sample collection during each visit. |
Who may qualify
- Ages
- 21 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Age 21-50 years
- Daily use of nicotine-containing electronic cigarettes for ≥ 6 months
- Ability to abstain from nicotine for at least 12 hours prior to study visits
- Fluent in English
- Willingness to complete two in-person laboratory visits and all study procedures
Key exclusion criteria (9 listed)
- Use of combustible cigarettes or other tobacco/nicotine products on more than 5 of the past 30 days
- Current enrollment in a nicotine cessation program or intent to quit in the next 30 days
- Neurological conditions affecting eye movements (seizure disorder, movement disorders, head injury with loss of consciousness)
- Normal or corrected-to-normal vision required; significant uncorrected visual impairment or ocular conditions affecting eye tracking
- Cardiovascular conditions for which nicotine use is contraindicated, substance use disorder (other than nicotine), or current nicotine cessation treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AvoidanceAlso: AvoidedAbstain from caffeine products | Behavioural | Basic science (e-cigarette smoking, eye movement testing) |
| Biospecimen CollectionAlso: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen CollectionUndergo blood sample collection | Procedure or surgery | Basic science (e-cigarette smoking, eye movement testing) |
| Cigarette SmokingComplete self-administer 5% nicotine non-mint menthol pods via an e-cigarette device | Behavioural | Basic science (e-cigarette smoking, eye movement testing) |
| Eye Movement MeasurementComplete eye movement testing | Procedure or surgery | Basic science (e-cigarette smoking, eye movement testing) |
| Healthcare ActivityAlso: Health Care, Health Care Activity, HealthcareObtain sleep | Behavioural | Basic science (e-cigarette smoking, eye movement testing) |
| Questionnaire AdministrationAncillary studies | Other | Basic science (e-cigarette smoking, eye movement testing) |
| Refrain from SmokingAlso: Abstain from Smoking, Abstinence from Cigarette Smoking, Abstinence from Cigarettes, Smoking AbstinenceAbstain from nicotine | Behavioural | Basic science (e-cigarette smoking, eye movement testing) |
| VapingAlso: VapeComplete ad-libitum e-cigarette vaping | Other | Basic science (e-cigarette smoking, eye movement testing) |
| Standardized E-Cigarette Nicotine AdministrationParticipants use a e-cigarette 5.0% nicotine mint menthol pods. Visit 1: 5-minute guided puffing session (standardized protocol). Visit 2: 5-minute guided session followed by 30-minute ad-libitum vaping phase. Puffing topography monitored via SPA-Neo device. | Drug | Basic science (e-cigarette smoking, eye movement testing) |
Primary outcome
Change in prosaccade latency and velocity
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration, assessed up to completion of visit 2, up to 3 weeks
Reliability will be assessed using intraclass correlation coefficients (ICCs). Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures analysis of variance (ANOVA), as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.
Change in antisaccade error rate and latency
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.
Change in smooth pursuit gain across two laboratory sessions
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.
Change in oculomotor performance
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.
Plasma nicotine maximum concentration
Time frame: Up to completion of visit 2, up to 3 weeks
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Time to maximum concentration of plasma nicotine
Time frame: Up to completion of visit 2, up to 3 weeks
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Plasma nicotine area under the curve
Time frame: Up to completion of visit 2, up to 3 weeks
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Subjective drug liking ratings
Time frame: Up to completion of visit 2, up to 3 weeks
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between subjective ratings and behavioral economic measures will be examined using correlation and regression analyses.
4 secondary outcomes
Electronic (E)-cigarette intensity demand
Time frame: Up to completion of visit 2, up to 3 weeks
E-cigarette Omax
Time frame: Up to completion of visit 2, up to 3 weeks
E-cigarette demand breakpoint
Time frame: Up to completion of visit 2, up to 3 weeks
Change in Minnesota Nicotine Withdrawal Scale scores
Time frame: From baseline and following nicotine administration, assessed up to completion of visit 2, up to 3 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- The JameslineLink provided by the sponsor.
Related trials for Cigarette Smoking-Related Carcinoma
Not yet recruitingPhase 1
PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis
Cigarette Smoking-Related Carcinoma
RecruitingPhase 3
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Cigarette Smoking-Related Carcinoma
Not yet recruitingPhase 3
iCanQuit Smoking Cessation Among Hispanic Adults
Cigarette Smoking-Related Carcinoma
Not yet recruiting
Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers
Cigarette Smoking-Related Carcinoma
RecruitingEarly Phase 1
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
Cigarette Smoking-Related Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The Ohio State University Comprehensive Cancer Center contact
Patrick Tomko, PhD, CSCS principal investigator
Ohio State University Comprehensive Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Avoidance, Biospecimen Collection and Cigarette Smoking in people with Cigarette Smoking-Related Carcinoma, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact The Ohio State University Comprehensive Cancer Center (800-293-5066, OSUCCCClinicaltrials@osumc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in prosaccade latency and velocity (time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration, assessed up to completion of visit 2, up to 3 weeks). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.